Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates

Christopher Turner, MD, Vice President, Clinical Science presents Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates at the 2016 annual International Kidney Cancer Symposium.